American Heart Association: Up to 5 Cups of Caffeinated Coffee Daily Safe for Heart, But Energy Drinks Pose Risks

The American Heart Association has released a new scientific statement, published in its flagship journal Circulation, clarifying the cardiovascular effects of caffeine. The statement, titled “Caffeine and Cardiovascular Disease,” provides a comprehensive review of recent research on caffeine consumption, primarily from coffee, and its impact on heart health.

According to the statement, for most adults, consuming up to 400 mg of caffeine per day — equivalent to about five 8-ounce cups of brewed caffeinated coffee — is safe and does not increase cardiovascular risk. In fact, moderate coffee intake was associated with a lower risk of several conditions, including Type 2 diabetes, heart disease, stroke, and heart failure. However, the benefits appear to diminish when coffee is consumed with added sugars, syrups, or cream, which may negate some positive effects.

The writing group, chaired by Dr. Gregory M. Marcus of the University of California, San Francisco, emphasized that while coffee is the primary source of caffeine for many adults, other sources such as energy drinks and shots contain much higher concentrations. Energy drink shots can have 40-69 mg of caffeine per fluid ounce, three to four times more than regular coffee. These high doses have been linked to increased blood pressure and irregular heart rhythms, particularly in healthy young adults.

The statement highlights that individual responses to caffeine vary widely due to genetics, metabolism, age, and tolerance. Short-term effects can include temporary rises in blood pressure, heart rate, and alertness, as well as palpitations or sleep disruption. The research also notes that unfiltered coffee (e.g., French press, espresso) contains cafestol, a compound that may raise LDL (“bad”) cholesterol, while paper-filtered or instant coffee does not.

The American Heart Association’s 2026 Dietary Guidance did not include specific caffeine recommendations due to insufficient data, but this statement underscores the need for more randomized controlled trials, especially on energy drinks and other caffeinated products. The full manuscript is available at https://www.ahajournals.org/doi/10.1161/CIR.0000000000001221.